Enzene Biosciences, a contract development & manufacturing organization (CDMO), launched its first manufacturing site in the U.S., in Hopewell, NJ. The site is expected to be operational in June 2024. The 54,000 sq.-ft. campus is the first biologics-focused continuous manufacturing base set up by an Indian firm in the U.S. Himanshu Gadgil, CEO, Enzene Biosciences said, “While the USA is home to most of the novel molecules that are the principal ingredients in creating many life-saving ...